ArticleFrontiers in oncology2022
Differentiation Between Benign and Metastatic Breast Lymph Nodes Using Apparent Diffusion Coefficients.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic Test Accuracy of Apparent Diffusion Coefficient in Evaluation of Breast Cancer Lymph Node Metastasis: A Systematic Review and Meta-Analysis.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- Diagnostic Potential of Apparent Diffusion Coefficient-Based Lymph Node Classification in Breast Cancer Patients Undergoing [Diagnostics (Basel, Switzerland) · 2026Article
- Differentiating lymph node status in malignant melanoma: the role of apparent diffusion coefficient ratio in diffusion-weighted MRI - a prospective diagnostic study.BMC medical imaging · 2026Article
- Quantitative metrics of mean apparent propagator magnetic resonance imaging in the diagnosis of axillary lymph node metastasis in breast cancer.Quantitative imaging in medicine and surgery · 2025Article
- Imaging-Based Pre-Operative Differentiation of Ovarian Tumours-A Retrospective Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2025Article
- Axillary Lymphadenopathy after COVID-19 Vaccination: Follow-up for Enlarged Lymph Nodes on MR Imaging.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025Article
- Outcome prediction of SSTR-RADS-3A and SSTR-RADS-3B lesions in patients with neuroendocrine tumors based onJournal of cancer research and clinical oncology · 2024Article
- Update on DWI for Breast Cancer Diagnosis and Treatment Monitoring.AJR. American journal of roentgenology · 2024Review
- Quantitative evaluation of diffusion-weighted MRI for differentiating benign and malignant thyroid nodules larger than 4 cm.BMC medical imaging · 2023Article
- The road to breast cancer screening with diffusion MRI.Frontiers in oncology · 2023Review
- Axillary Lymphadenopathy after Pfizer-BioNTech and Moderna COVID-19 Vaccination: MRI Evaluation.Radiology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The aim of this study was to determine the range of apparent diffusion coefficient (ADC) values for benign axillary lymph nodes in contrast to malignant axillary lymph nodes, and to define the optimal ADC thresholds for three different ADC parameters (minimum, maximum, and mean ADC) in differentiating between benign and malignant lymph nodes. This retrospective study included consecutive patients who underwent breast MRI from January 2017-December 2020. Two-year follow-up breast imaging or histopathology served as the reference standard for axillary lymph node status. Area under the receiver operating characteristic curve (AUC) values for minimum, maximum, and mean ADC (min ADC, max ADC, and mean ADC) for benign
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.